시장보고서

상품코드

1820146

리포솜 독소루비신 시장 보고서 : 제품별, 용도별, 지역별(2025-2033년)

Liposomal Doxorubicin Market Report by Product (Doxil/Caelyx, Lipodox, Myocet, and Others), Application (Leukemia, Bone Sarcoma, Breast Cancer, Endometrial Cancer, Kidney Cancer, Multiple Myeloma, Kaposi Sarcoma, and Others), and Region 2025-2033

발행일: 2025년 09월 | 리서치사:

IMARC | 페이지 정보: 영문 139 Pages | 배송안내 : 2-3일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 리포솜 독소루비신 시장 규모는 2024년 13억 4,000만 달러에 달했습니다. 향후 IMARC Group은 2033년까지 20억 6,000만 달러에 달할 것으로 예상하며, 2025년부터 2033년까지 4.9%의 연평균 성장률(CAGR)을 보일 것으로 전망하고 있습니다.

리포솜 독소루비신은 다양한 자가면역질환과 간, 유방, 자궁내막, 위, 신장암 치료에 사용되는 화학요법제입니다. 체내 암세포의 증식을 막거나 지연시키는 기능을 합니다. 이 약은 페그화 리포솜 지방으로 싸여 있으며, 주사를 통해 정맥으로 투여됩니다. 독소루비신이라는 약물은 암세포가 분열-증식하는 데 필요한 효소를 차단하고, 리포솜을 통해 약물이 혈류에 오래 머물러 암세포에 도달해 효과를 높입니다. 약의 복용량은 환자의 체중, 신장, 일반적인 건강 상태에 따라 다릅니다. 리포솜 독소루비신은 기존에 사용되던 약제에 비해 독성, 골수억제, 탈모증, 메스꺼움 등이 적습니다.

리포솜 독소루비신 시장 동향:

골육종, 다발성 골수종, 난소암, 자가면역결핍증후군(AIDS) 관련 카포시육종과 같은 만성질환의 전 세계 유병률 증가는 시장 성장을 촉진하는 중요한 요인 중 하나입니다. 이는 노동 인구의 대다수가 좌식 생활과 바쁜 스케줄로 인해 이러한 질병의 발생이 크게 증가하여 리포솜 독소루비신 의약품의 수요에 긍정적인 영향을 미치고 있습니다. 또한, 암 치료에 대한 대중의 인식이 높아짐에 따라 시장 성장을 촉진하고 있습니다. 패러다임 나노약물, 개량형 화학요법제 개발 등 다양한 발전이 또 다른 성장 촉진요인으로 작용하고 있습니다. 이러한 기술 혁신은 체내에서 약물의 부위별 전달 및 방출 제어를 용이하게 합니다. 그 외의 요인으로는 특히 신흥 경제국의 의료 인프라가 크게 개선되고, 종양학 분야의 광범위한 연구개발(R&D) 활동 등이 시장 성장을 견인할 것으로 예상됩니다.

본 보고서에서 답변하는 주요 질문

세계 리포솜 독소루비신 시장은 지금까지 어떻게 성장해왔고, 앞으로 어떻게 성장할 것인가?
COVID-19가 세계 리포솜 독소루비신 시장에 미치는 영향은?
주요 지역 시장은?
제품별 시장 분석은?
용도별 시장 내역은?
산업 가치사슬의 다양한 단계는 무엇인가?
업계의 주요 촉진요인과 과제는 무엇인가?
세계 리포솜 독소루비신 시장 구조와 주요 기업은?
업계 내 경쟁은 어느 정도인가?

Liposomal doxorubicin is a chemotherapy drug used for the treatment of various autoimmune disorders and cancer of the liver, breast, endometrial, gastric and kidney. It functions by stopping or slowing cancer cell growth in the body. The medication is wrapped in a fatty covering of pegylated liposome and is administered intravenously through an injection. The doxorubicin drug blocks the enzymes required by cancer cells to divide and grow and the liposomes ensure that the drug stays in the bloodstream longer and reaches the cancer cells for enhanced efficacy. The dosage of the medication varies on the weight, height and general health of the patient. In comparison to the traditionally used drugs, liposome doxorubicin exhibits lesser toxicity, myelosuppression, alopecia and nausea.

Liposomal Doxorubicin Market Trends:

The increasing prevalence of chronic medical ailments, such as bone sarcoma, multiple myeloma, ovarian cancer and Autoimmune Deficiency Syndrome (AIDS)-related Kaposi sarcoma, across the globe is one of the key factors driving the market growth. This can be attributed to the sedentary lifestyles and hectic schedules of a majority of the working population, which, in turn, is significantly increasing the occurrence of these disorders and positively impacting the demand for liposomal doxorubicin drugs. Moreover, rising awareness among the masses regarding the available treatment alternatives for cancer is providing a thrust to the growth of the market. Various advancements, such as the development of paradigmatic nanodrugs and improved chemotherapeutic agents, are acting as other growth-inducing factors. These innovations facilitate site-specific delivery and controlled release of the drug in the body. Other factors, including significant improvements in the healthcare infrastructure, especially of the developing economies, along with extensive research and development (R&D) activities in the field of oncology, are anticipated to drive the market toward growth.

Key Market Segmentation:

Breakup by Product:

Doxil/Caelyx
Lipodox
Myocet
Others

Breakup by Application:

Leukemia
Bone Sarcoma
Breast Cancer
Endometrial Cancer
Kidney Cancer
Multiple Myeloma
Kaposi Sarcoma
Others

Breakup by Region:

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
Latin America
- Brazil
- Mexico
- Others
Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Baxter International Inc., Cipla Inc., Johnson & Johnson, Merck KGaA, Pfizer Inc., Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd, TTY Biopharm Company Limited and Zydus Cadila.

Key Questions Answered in This Report:

How has the global liposomal doxorubicin market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global liposomal doxorubicin market?
What are the key regional markets?
What is the breakup of the market based on the product?
What is the breakup of the market based on the application?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global liposomal doxorubicin market and who are the key players?
What is the degree of competition in the industry?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Liposomal Doxorubicin Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Product

6.1 Doxil/Caelyx
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
6.2 Lipodox
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
6.3 Myocet
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
6.4 Others
- 6.4.1 Market Trends
- 6.4.2 Market Forecast

7 Market Breakup by Application

7.1 Leukemia
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Bone Sarcoma
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
7.3 Breast Cancer
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
7.4 Endometrial Cancer
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
7.5 Kidney Cancer
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
7.6 Multiple Myeloma
- 7.6.1 Market Trends
- 7.6.2 Market Forecast
7.7 Kaposi Sarcoma
- 7.7.1 Market Trends
- 7.7.2 Market Forecast
7.8 Others
- 7.8.1 Market Trends
- 7.8.2 Market Forecast

8 Market Breakup by Region

8.1 North America
- 8.1.1 United States
  - 8.1.1.1 Market Trends
  - 8.1.1.2 Market Forecast
- 8.1.2 Canada
  - 8.1.2.1 Market Trends
  - 8.1.2.2 Market Forecast
8.2 Asia-Pacific
- 8.2.1 China
  - 8.2.1.1 Market Trends
  - 8.2.1.2 Market Forecast
- 8.2.2 Japan
  - 8.2.2.1 Market Trends
  - 8.2.2.2 Market Forecast
- 8.2.3 India
  - 8.2.3.1 Market Trends
  - 8.2.3.2 Market Forecast
- 8.2.4 South Korea
  - 8.2.4.1 Market Trends
  - 8.2.4.2 Market Forecast
- 8.2.5 Australia
  - 8.2.5.1 Market Trends
  - 8.2.5.2 Market Forecast
- 8.2.6 Indonesia
  - 8.2.6.1 Market Trends
  - 8.2.6.2 Market Forecast
- 8.2.7 Others
  - 8.2.7.1 Market Trends
  - 8.2.7.2 Market Forecast
8.3 Europe
- 8.3.1 Germany
  - 8.3.1.1 Market Trends
  - 8.3.1.2 Market Forecast
- 8.3.2 France
  - 8.3.2.1 Market Trends
  - 8.3.2.2 Market Forecast
- 8.3.3 United Kingdom
  - 8.3.3.1 Market Trends
  - 8.3.3.2 Market Forecast
- 8.3.4 Italy
  - 8.3.4.1 Market Trends
  - 8.3.4.2 Market Forecast
- 8.3.5 Spain
  - 8.3.5.1 Market Trends
  - 8.3.5.2 Market Forecast
- 8.3.6 Russia
  - 8.3.6.1 Market Trends
  - 8.3.6.2 Market Forecast
- 8.3.7 Others
  - 8.3.7.1 Market Trends
  - 8.3.7.2 Market Forecast
8.4 Latin America
- 8.4.1 Brazil
  - 8.4.1.1 Market Trends
  - 8.4.1.2 Market Forecast
- 8.4.2 Mexico
  - 8.4.2.1 Market Trends
  - 8.4.2.2 Market Forecast
- 8.4.3 Others
  - 8.4.3.1 Market Trends
  - 8.4.3.2 Market Forecast
8.5 Middle East and Africa
- 8.5.1 Market Trends
- 8.5.2 Market Breakup by Country
- 8.5.3 Market Forecast

9 SWOT Analysis

9.1 Overview
9.2 Strengths
9.3 Weaknesses
9.4 Opportunities
9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

11.1 Overview
11.2 Bargaining Power of Buyers
11.3 Bargaining Power of Suppliers
11.4 Degree of Competition
11.5 Threat of New Entrants
11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

13.1 Market Structure
13.2 Key Players
13.3 Profiles of Key Players
- 13.3.1 Baxter International Inc.
  - 13.3.1.1 Company Overview
  - 13.3.1.2 Product Portfolio
  - 13.3.1.3 Financials
  - 13.3.1.4 SWOT Analysis
- 13.3.2 Cipla Inc.
  - 13.3.2.1 Company Overview
  - 13.3.2.2 Product Portfolio
  - 13.3.2.3 Financials
  - 13.3.2.4 SWOT Analysis
- 13.3.3 Johnson & Johnson
  - 13.3.3.1 Company Overview
  - 13.3.3.2 Product Portfolio
  - 13.3.3.3 Financials
  - 13.3.3.4 SWOT Analysis
- 13.3.4 Merck KGaA
  - 13.3.4.1 Company Overview
  - 13.3.4.2 Product Portfolio
  - 13.3.4.3 Financials
  - 13.3.4.4 SWOT Analysis
- 13.3.5 Pfizer Inc.
  - 13.3.5.1 Company Overview
  - 13.3.5.2 Product Portfolio
  - 13.3.5.3 Financials
  - 13.3.5.4 SWOT Analysis
- 13.3.6 Sun Pharmaceutical Industries Ltd
  - 13.3.6.1 Company Overview
  - 13.3.6.2 Product Portfolio
  - 13.3.6.3 Financials
  - 13.3.6.4 SWOT Analysis
- 13.3.7 Teva Pharmaceutical Industries Ltd
  - 13.3.7.1 Company Overview
  - 13.3.7.2 Product Portfolio
  - 13.3.7.3 Financials
  - 13.3.7.4 SWOT Analysis
- 13.3.8 TTY Biopharm Company Limited
  - 13.3.8.1 Company Overview
  - 13.3.8.2 Product Portfolio
  - 13.3.8.3 Financials
- 13.3.9 Zydus Cadila
  - 13.3.9.1 Company Overview
  - 13.3.9.2 Product Portfolio

리포솜 독소루비신 시장 보고서 : 제품별, 용도별, 지역별(2025-2033년)

Liposomal Doxorubicin Market Report by Product (Doxil/Caelyx, Lipodox, Myocet, and Others), Application (Leukemia, Bone Sarcoma, Breast Cancer, Endometrial Cancer, Kidney Cancer, Multiple Myeloma, Kaposi Sarcoma, and Others), and Region 2025-2033

리포솜 독소루비신 시장 동향:

본 보고서에서 답변하는 주요 질문

목차

제1장 서문

제2장 분석 범위와 방법

제3장 주요 요약

제4장 소개

제5장 세계의 리포솜 독소루비신 시장

제6장 시장 내역 : 제품별

제7장 시장 내역 : 용도별

제8장 시장 내역 : 지역별

제9장 SWOT 분석

제10장 밸류체인 분석

제11장 Porter's Five Forces 분석

제12장 가격 분석

제13장 경쟁 구도